** single-gpage.php **
** content-gpage.php **


Coeliac disease

  

Coeliac disease is a common digestive condition where a person has an adverse reaction to gluten.


Revision of Recommendations COVID-19 Non-biopsy policy for adults with positive coeliac serology

UHCW has adopted the BSG non biopsy protocol during COVID-19 (see flow chart below)

OGD and D2 biopsy is no longer performed if patient < 55 and no alarm symptoms – instead perform EMA test if tTG raised and refer to dietetics

What we know about using non-biopsy protocol to date:
  • IgA tissue transglutaminase (tTG) level of ≥10x the upper limit of normal (ULN) is more than 90% predictive of villous atrophy in the adult population.
  • In young people, anti-endomysial antibody test (EMA IgA) testing in a second blood sample serves to reduce the likelihood of a false-positive tTG result and/or the possibility of a recording a transiently elevated tTG titre.
  • Where EMA is not available a 2nd tTG is acceptable.

There is an unknown risk to undiagnosed individuals who have coeliac disease but are not on a Gluten Free Diet. This is likely to be comparable to a patient with coeliac disease that has on-going villous atrophy.

The risks are of increased :

  • Haematinic deficiency
  • Reduced bone mineral density
  • Reduced quality of life
  • Increased risk of small bowel lymphoma.

 

Non biopsy protocol

Reference: British Society of Gastroenterology Suggested Protocol Pending Revisions of the BSG Coeliac Disease Guidelines

(Visited 295 times, 29 visits today)

Leave feedback